Biopartnering Seminar - Increasing Adoption of Kadcyla for Metastatic HER-2 Positive Breast Cancer

BitBios - Dec 9th
Tuesday, December 9, 2014 - 6:30pm

Breast cancer is one of the most common cancers amongst women in Canada, with 157,000 women living with breast cancer and an additional 24,400 cases estimated for 2014.  In Canada, 1 in every 30 women will die from stage IV (metastatic) breast cancer. Genotypes of breast cancer play a significant factor when determining tumor aggressiveness and treatment pathways. One genotype, the overexpression of human epidermal growth factor-2 (HER2), occurs in 20-25% of breast cancer cases and is more aggressive than other types.

Metastatic HER2+ breast cancer is generally treated with HER2-targeted monoclonal antibodies (Herceptin, Perjeta) and/or various chemotherapies. However, in September 2013, the revolutionary new antibody drug conjugate Kadcyla was approved by Health Canada for use in metastatic HER2+ breast cancer. Kadcyla combines the specificity of an antibody (Herceptin) with the cell-killing potential of a chemotherapy drug (mertansine). This increases selectivity and the cytotoxic effect of anti-cancer therapies, increasing average overall survival by 5.8 months when compared to the previous standard of care.  

On  October 17, 2014, the Ontario Ministry of Health announced new public funding for Kadcyla which gives expanded access for patients. This new public funding of Kadcyla has opened an opportunity for existing 2nd line patients to now receive Kadcyla as 3rd line treatment. Our plan is to implement a targeted sales strategy which will focus on converting the pre-existing 2nd line (Herceptin and Tykerb) patient population to Kadcyla. This strategy will highlight the new reimbursement status of Kadcyla, as well as its superior efficacy and safety profile, subsequently increasing Kadcyla adoption.  

Location: Instructional Centre, Room 120

Presented By: BIT BioSolutions

Team Members: Jill Eeuwes, Lidya Ercag, Joshua Hoang, Daniel Junik, Sabrina Paez-Parent

All welcome! Light refreshments served outside of Room 120 at 6pm.